China's modern medicine leads public health for the first time at Puli Farming Expo
Hong Kong, April 22, 2024 /Mainland Community/ -- On April 13, 2024, Puli Agricultural Company Limited (HKEX: 1498, hereinafter referred to as “Pili Farming Party”) will make its debut as an exhibitor at the First China International Consumer Fair (hereinafter referred to as “Consumer Expo”), one of the four largest national trade fairs in China. With its unique brand charm, it will be the focus of this exhibition. The HKTDC will relaunch its inaugural exhibition, which will promote the internationalisation strategy of the agricultural sector in line with the theme of “sharing open opportunities and creating a better life together”.
Pelinong announced the termination of the placement agreement
Peilinong itself (01498) announced that on April 12, 2024 (after the trading period), the placement agent delivered a written notice of termination to terminate the placement agreement in accordance with the terms of the placement agreement. Upon termination of the placement agreement, all of the obligations of each party to the placement agreement will be terminated and no party shall bring any claim against the other party in respect of any matter or event arising out of or relating to the placement agreement, except for any prior violator of any obligation under the placement agreement.
Pelinon's side (01498): Termination of placement agreement
Pelinong Corporation (01498) announced that on April 12, 2024 (after the trading period), the placement agent was delivered...
PuraPharm's Net Loss Shrinks in 2023; Revenue Falls 9%
PuraPharm Corporation (HKG:1498) saw a decline in attributable loss for the year ended Dec. 31, 2023, to HK$106.1 million from HK$120.2 million during the year-ago period, a filing posted on the Hong
Pelinong (01498) plans to sell a maximum of 50 million shares at a 6.02% discount to raise about HK$37.7 million
Peilinong (01498) issued an announcement. On March 28, 2024, the company and the placement agent signed an placement agreement...
Peilinong Benfang (01498) announced 2023 results. Net loss of HK$106 million narrowed 11.76% year over year
Pelinong Benfang (01498) announced its 2023 results, with revenue of approximately HK$407 million, a year-on-year decrease of 9.2%...
PURAPHARM: ANNOUNCEMENT OF FINAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
PURAPHARM: POSTPONEMENT OF BOARD MEETING
Pelinong Group (01498.HK) plans to hold a board meeting on March 25 to approve the annual results
Glonghui, March 13, 丨 Pelinong (01498.HK) announced that the board of directors meeting will be held on March 25, 2024 (Monday) to consider and approve, as appropriate, the Group's annual results results for the year ended 31 December 2023, publish an announcement of the annual results, and consider payment of a final dividend (if any).
CICC: The pharmaceutical sector has entered the value investment range. It is recommended to focus on overseas exports and opportunities to increase the localization rate
CICC released a research report saying that after more than 2 years of systematic adjustments, the pharmaceutical sector has entered the value investment range.
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
Pioneer Securities Pharmaceutical's 24-year Strategy: Risks have been fully released, and subsequent industry valuations are expected to rise steadily
The Zhitong Finance App learned that Pioneer Securities released a research report saying that due to more scientific collection rules, after the collection gradually covered a large stock of generic drugs/high-value consumables, the performance was clear, and new performance growth points were formed after innovative products were launched one after another, and the drugs/device-related companies in the hospital will usher in a new growth cycle after their performance stabilizes.
It's a little warm this Christmas|Pili Farming Party & Security 2023 community event ends warmly
Hong Kong, December 29, 20232/Beauty Communication/ -- In this Christmas season full of surprises and warmth, Perinese agricultural brand Oncozac, successfully organized a Christmas table flower workshop on the theme of “Christmas table flowers • herbs” on December 15. The brand cordially invited 40 community members to gather at Oncozac's first flagship store (1st Floor, Star Shop, 3 Salisbury Road, Tsim Sha Tsui) to experience the comfort and joy of the craft activities and spend a warm and pleasant afternoon together. At 2pm on the same day, taste
Wu Han of Zhongkang Technology: The key to solving the development problems of the traditional Chinese medicine industry is to break the “island effect”
The first Traditional Chinese Medicine Ecological Conference is expected to bring new opportunities and perspectives to enterprise development and industrial upgrading.
Guojin Securities: Sector-suppressing factors, clear pharmaceuticals are expected to welcome a major inflection point in the reversal of economic sentiment
The Zhitong Finance app learned that Guojin Securities released a research report saying that after a long period of decline and adjustment, the pharmaceutical sector ushered in a major inflection point from the second half of 2023 to 2024, and various factors such as policy, performance, and chips bottomed out and reversed.
Guotai Junan: The pharmaceutical sector valuation system has entered a small cycle of grasping business operations during a relatively stable period
The Zhitong Finance App learned that Guotai Junan released a research report saying that in 2019-2023, the collection, epidemic, etc. affected industries. It is anticipated that 2024, regardless of whether it has had the greatest positive or negative impact, has passed, returning to the main logic driven by healthcare demand.
Guoxin Securities's 24-year Pharmaceutical Strategy: Good Timing+High Returns, Positioning the Second Wave of Global Innovation Leaders
Guoxin Securities believes that 2023Q4 is the best time to lay out the pharmaceutical market for the next three years.
Everbright Securities: Four Advantages of Accelerating Transformation and Upgrading of the Traditional Chinese Medicine Industry, Value Revaluation
The Zhitong Finance app learned that Everbright Securities published a research report saying that traditional Chinese medicine has rich clinical positioning and broad market space. Under medical reform policies and industry standards, quality, safety, and efficacy have continued to improve.
Bank of China Fund Zheng Ning: Optimistic about the pharmaceutical industry's reversal, in-hospital product-side companies, especially innovative drugs, are worth paying attention to
Recently, Bank of China Fund Zheng Ning said in an in-depth interview that in the next rise in the pharmaceutical industry, the hospital's product-side companies, especially innovative drugs, are expected to take the lead.
CITIC Construction Investment: Positive year-on-year growth in pharmaceutical revenue in the first three quarters favors prescription drugs, traditional Chinese medicine, etc.
The overall sector's revenue in the first three quarters of 2023 achieved positive year-on-year growth, and the growth rate declined in the third quarter. The growth rate slowed mainly due to increased compliance requirements, but the downturn was not overshadowed, and immediate demand and innovation drove the industry's Q3 revenue to continue to grow.
No Data